Back to Directory
Mazdutide
Metabolic & Weight ManagementGLP-1/Glucagon dual agonist for obesity and NASH, weekly dosing.
Key Benefits
- ✓Significant weight loss (up to 15%)
- ✓Reduces liver fat
- ✓Treats obesity and NASH
- ✓Weekly dosing
- ✓Dual mechanism
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly
Typical Duration
Clinical development
Detailed Protocol
Under clinical development. Weekly subcutaneous injection in trials. Phase 2 completed, phase 3 planning.
About Mazdutide
Mazdutide (IBI362) is a long-acting GLP-1/glucagon dual receptor co-agonist. Phase 2 trials showed significant weight loss and NASH improvements. Being developed in China and globally.
Research Notes
Phase 2 trials showed dose-dependent weight loss up to 15% and liver fat reductions. Development active in China. Global trials planned.
Potential Side Effects
- •Nausea
- •Diarrhea
- •Vomiting
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.